Home | Welcome to Contract Pharma   
Last Updated Monday, April 21 2014
Print

Financial Report: Roche



Published January 30, 2013
Roche

FY Revenues: $49.8 billion (+1%)

FY Earnings: $10.7 billion (+5%)

Comments: Pharmaceutical Division sales were $38.6 billion, up 2%. MabThera/Rituxan sales were $7.3 billion (+9% in local currencies). Herceptin sales were $6.4 billion (+11% lc). Avastin sales were $6.3 billion (+6% lc). Diagnostics Division revenues were flat at $11.2 million. R&D spend was $8.2 billion, up 2%.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On